Integrating a quinone substructure into histone deacetylase inhibitors to cope with Alzheimer's disease and cancer-Reference-Cited by-同舟云学术

Integrating a quinone substructure into histone deacetylase inhibitors to cope with Alzheimer's disease and cancer

Published:2024 Issue:6 Volume:15 Page:2045-2062
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Guardigni Melissa¹,Greco Giulia²,Poeta Eleonora³,Santini Alan¹,Tassinari Elisa¹,Bergamini Christian³,Zalambani Chiara³,De Simone Angela⁴^ORCID,Andrisano Vincenza¹,Uliassi Elisa³^ORCID,Monti Barbara³,Bolognesi Maria Laura³^ORCID,Fimognari Carmela¹,Milelli Andrea¹^ORCID

Affiliation:

1. Department for Life Quality Studies, Alma Mater Studiorum – University of Bologna, 47921 Rimini, Italy

2. Department of Chemistry “Giacomo Ciamician”, Alma Mater Studiorum – University of Bologna, 40129, Bologna, Italy

3. Department of Pharmacy and Biotechnology, Alma Mater Studiorum – University of Bologna, 40126 Bologna, Italy

4. Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy

Abstract

Rationally designed quinone-based histone deacetylase inhibitors have been characterized in vitro, showing potential against two of the most devastating diseases of the 21st century.

Funder

Università di Bologna

Università degli Studi di Torino

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/MD/D4MD00175C

Reference50 articles.

1. Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight

2. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

3. Recent developments of HDAC inhibitors: Emerging indications and novel molecules

4. Understanding the Role of Histone Deacetylase and their Inhibitors in Neurodegenerative Disorders: Current Targets and Future Perspective

5. HDAC2 negatively regulates memory formation and synaptic plasticity